WO2000059507A1 - Agents servant a prevenir l'obesite - Google Patents

Agents servant a prevenir l'obesite Download PDF

Info

Publication number
WO2000059507A1
WO2000059507A1 PCT/JP1999/001748 JP9901748W WO0059507A1 WO 2000059507 A1 WO2000059507 A1 WO 2000059507A1 JP 9901748 W JP9901748 W JP 9901748W WO 0059507 A1 WO0059507 A1 WO 0059507A1
Authority
WO
WIPO (PCT)
Prior art keywords
biotin
obesity
weight gain
intake
preventives
Prior art date
Application number
PCT/JP1999/001748
Other languages
English (en)
Japanese (ja)
Inventor
Kazumi Osada
Kenji Tsunoda
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP9276089A priority Critical patent/JPH11116478A/ja
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to PCT/JP1999/001748 priority patent/WO2000059507A1/fr
Priority to AU29614/99A priority patent/AU2961499A/en
Publication of WO2000059507A1 publication Critical patent/WO2000059507A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to an antiobesity agent containing piotin as an active ingredient.
  • the present inventors have found that in the course of a study on the physiological role of biotin, the rate of weight gain of a model animal to which biotin was administered was significantly suppressed, and completed the present invention based on such findings.
  • the present invention is an antiobesity agent characterized by using biotin as an active ingredient.
  • Pyotin is a type of coenzyme known as vitamin H. It is well known that it acts as an essential coenzyme of lupoxylase. In terms of physiological effects, effects on cell growth and DNA synthesis have been reported, and a wide variety of research reports have been made on deficiency of biotin, including dermatitis, hair loss, and ataxia.
  • biotin significantly suppresses undesired weight gain caused by ingesting a high calorie single meal, ie, that biotin has an obesity-preventing effect. That is, the prevention of obesity according to the present invention refers to an effect of suppressing an undesired increase in weight that is observed when calories are excessively consumed, as described above.
  • the antiobesity agent of the present invention can be prepared in the form of a solid preparation or a liquid preparation as long as it can be taken orally.
  • a solid preparation containing biotin any of powder, granule and tablet forms can be prepared by a general production method.
  • Liquid preparations can also be prepared by mixing with commonly used bases and active ingredients.
  • the intake of It is preferably at least 200 g, preferably at least 400 g per day. With an intake of less than 200 X g, the effect of biotin on suppressing weight gain is not fully exerted.
  • microcrystalline cellulose and biotin were uniformly mixed in advance, other components were additionally mixed and granulated to prepare a high calorie granule.
  • microcrystalline cellulose and biotin were uniformly mixed in advance, other components were additionally mixed and granulated to prepare a high calorie granule.
  • Example 1 The following test was performed using an SD rat (oss) body weight of 400 g.
  • the animals of Example 1, Example 2, and Comparative Example 1 were each fed 10 g Z days each in three groups of six animals each. Since egg white, which is a protein source in each diet, has the property of adsorbing biotin, the comparative example in which 150 g of biotin adsorbed on 2 O mg of egg white was added was used as a blank for the amount of biotin. . Therefore, the amount of effective biotin contained in each example is equivalent to 50 g / 100 g of the bait in Example 1 and to 600 g / 100 g of the bait in Example 2.
  • FIG. 1 shows the average food consumption of the granules of Examples and Comparative Examples in each SD rat group from day 60 to day 70 after the start of the test. The vertical line on the graph indicates the standard deviation.
  • FIG. 2 is a graph showing the average weight gain of the SD rats fed with biotin for 70 days, in which the vertical axis represents the weight gain and the horizontal axis represents the experimental period (weeks).
  • ⁇ indicates the results when the granules of Comparative Example 1 were used
  • ⁇ indicates the results when the granules of Example 1 were used
  • ⁇ indicates the results when the granules of Example 2 were used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Préparations orales exerçant un effet de prévention de l'obésité sur la base d'un principe différent de l'exercice physique ou de la limitation de l'apport calorique. Ces préparations contenant biotine en tant qu'ingrédient actif, permettent d'empêcher efficacement la prise indésirable de poids.
PCT/JP1999/001748 1997-10-08 1999-04-02 Agents servant a prevenir l'obesite WO2000059507A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9276089A JPH11116478A (ja) 1997-10-08 1997-10-08 肥満防止剤
PCT/JP1999/001748 WO2000059507A1 (fr) 1997-10-08 1999-04-02 Agents servant a prevenir l'obesite
AU29614/99A AU2961499A (en) 1997-10-08 1999-04-02 Obesity preventives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9276089A JPH11116478A (ja) 1997-10-08 1997-10-08 肥満防止剤
PCT/JP1999/001748 WO2000059507A1 (fr) 1997-10-08 1999-04-02 Agents servant a prevenir l'obesite

Publications (1)

Publication Number Publication Date
WO2000059507A1 true WO2000059507A1 (fr) 2000-10-12

Family

ID=26440117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/001748 WO2000059507A1 (fr) 1997-10-08 1999-04-02 Agents servant a prevenir l'obesite

Country Status (3)

Country Link
JP (1) JPH11116478A (fr)
AU (1) AU2961499A (fr)
WO (1) WO2000059507A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US9145453B2 (en) * 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) * 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
EP3595701A4 (fr) 2017-03-13 2021-01-06 SDG, Inc. Nanoparticules à base de lipides à stabilité améliorée
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192090A (ja) * 1991-12-04 1993-08-03 Norin Suisansyo Kyushu Nogyo Shikenjo 単胃動物に対するビタミンｂ群の給与方法
JPH0995448A (ja) * 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192090A (ja) * 1991-12-04 1993-08-03 Norin Suisansyo Kyushu Nogyo Shikenjo 単胃動物に対するビタミンｂ群の給与方法
JPH0995448A (ja) * 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRAMER, TIM R.: "Effects of Biotin Deficiency on Polyunsaturated Fatty Acid Metabolism in Rats", J. NUTR., vol. 114, no. 11, 1984, pages 2047 - 2052, XP002919362 *

Also Published As

Publication number Publication date
JPH11116478A (ja) 1999-04-27
AU2961499A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
US6136339A (en) Food supplements and methods comprising lipoic acid and creatine
US5716926A (en) Composition of pyruvate and protein and method for increasing protein concentration in a mammal
CN100415224C (zh) 包含脂肪酸和氨基酸的组合物
US5919767A (en) Use of pyruvate and anti-cortisol compounds in a method for enhancing physical endurance and athletic endurance in a mammal
EP0007691B1 (fr) Compositions à utiliser pour diminuer l'appétit de calories d'hydrates de carbone
US5888553A (en) Non-steroidal anabolic composition
US6221836B1 (en) Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
JPH0587052B2 (fr)
US4309445A (en) d-Fenfluramine for modifying feeding behavior
JP2002034592A (ja) 体内に吸収されやすい蛋白化−亜鉛の製造方法
JP5749880B2 (ja) Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
WO2002040035A1 (fr) Medicament contre le diabete
WO2009082883A1 (fr) Composition anti-obésité
WO2000059507A1 (fr) Agents servant a prevenir l'obesite
Faipoux et al. Yeast proteins enhance satiety in rats
WO2002094038A1 (fr) Produit dietetique satiant
JPS60186261A (ja) 固体状食品組成物
EP1093337B1 (fr) Supplements nutritifs comprenant de l'acide lipoique et de la creatine et methodes pour leur utilisation
JPS6049764A (ja) 食品組成物
JPH0995448A (ja) 血中ビオチン濃度の増加方法およびビオチン含有飲食品
CN110226756A (zh) 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法
EP1064858B1 (fr) Biopolymères non digestibles et/ou non-absorbables chimiquement dérivatisés en tant qu'antagonistes concurrentiels d'absorption intestinale de nutrients
JP2003261445A (ja) 血中中性脂肪低減剤
US6008253A (en) Use of 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity in a mammal
JPH07196485A (ja) 脂質代謝改善剤及び脂質代謝改善食品

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase